asininityandbeyond

[asininityandbeyond @asininitybeyond]

@tom_the_bomb__ “we expect these data will provide validation of our pre|CISION® technology in patients, by demonstrating that both our First + Second Gen molecules can effectively treat human cancers”

As confident a statement that #AVCT has ever made about its clinical drugs

Very telling

2/2

[asininityandbeyond @asininitybeyond]

@tom_the_bomb__ Seems to me that a cornerstone investment of >£4.5m is likely underwritten by the comfort that (explicitly stated or otherwise) AVA6103 is working exactly as expected

These statements, new indications + more sites basically confirm that for those on the outside IMO

1/2 #AVCT

[asininityandbeyond @asininitybeyond]

AVA6000 patient population is getting increasingly meaningful

Acknowledgment of this full ‘n’ group further supports my view that accelerated pathways for SGC (and maybe others) leverage the strong safety of the full trial, beyond just indication subsets

Very positive IMO #AVCT

[asininityandbeyond @asininitybeyond]

Everything falls into place from this statement

Its built on lab data. Informed by the success of A6K. It points to AVA6103 doing what we, co, Drs + patients all hoped

Its not over-confidence but an informed articulation of what #AVCT holds + how it should be valued (by BP).3/3

[asininityandbeyond @asininitybeyond]

Been busy with the day job recently but lots of positives coming from #AVCT now.

This CEO statement is incredible. Confidence abounds + much to parse from these 4 paragraphs alone!

Growing IP, rapid development, multiple commercial opps, broadening application of the tech.1/3

[asininityandbeyond @asininitybeyond]

However the root of all value is here:

“we believe [pre|CISION] is the only technology that is capable of delivering cancer treatment drugs directly to the tumor at the precise concentrations our payloads can achieve – and without triggering severe toxic side effects.” 2/3 #AVCT

[asininityandbeyond @asininitybeyond]

@SeanDentBsc No, they were rightly tight lipped

Ruairidh did make a comment referring to biopsies which implied confidence in getting them (recognising they are optional)

The new indications, high profile science day, Dr Spira’s confidence etc are all tells that things are going to plan IMO

[asininityandbeyond @asininitybeyond]

Science day…

Same old, same old?

Maybe share price-wise but more meaningful in terms of intangibles, IMO.

My first time at an #AVCT investor meeting in person - I live at least one border away from Piccadilly!

Overall, lots of familiar content but some key additions. 1/6

[asininityandbeyond @asininitybeyond]

@SeanDentBsc Hi Sean, it was laboured that AVA6000 went from 4:1 to 100:1 from mouse to human.

Mice have much more free FAP in plasma than man, leading to more cleavage in the blood stream.

6103 is already 99:1 in mice, so could be significantly higher in human, reading across from A6K.

[asininityandbeyond @asininitybeyond]

✅ #AVCT’s tech is dynamite
✅ Team is absurdly talented
✅ there’s a maturity to (pre)clinical + commercial progress
✅ taking time to do it right will pay back
✅ FDA = a friendly counterparty
✅ independent doctors are excited about 6103
✅ Nearterm: data + IP (+ deals?)

6/6

[asininityandbeyond @asininitybeyond]

- Richard Hughes was there facing off with investors… it’s a Science Day, he didn’t need to be.

Easy to tell ppl they should get to meetings in person but I know myself it’s hard for many.

So my somewhat independent take on #AVCT’s Science Day is:

5/6

[asininityandbeyond @asininitybeyond]

Interestingly, 6103 poster refers to DU145 prostate cancer; a PSA + PMSA negative subtype, so traditional Tx dont work. AVA6103 presents opportunity for primary + CUP

Staggering potential here - CUP success is both hugely lucrative + the pinnacle of platform valuation. 3/3 #AVCT

[asininityandbeyond @asininitybeyond]

Its becoming more likely #AVCT is setting up for a Cancer of Unknown Primary (CUP) component to the AVA6103 trial in Ph2 IMO

Suite of indications proving broad efficacy supports that, coupled with in-scope adeno + SC carcinoma histologies making up the majority of CUP cases.1/3

[asininityandbeyond @asininitybeyond]

It must be understood how critical tumour agnostic Tx is for rare cancer, cancer of unknown primary etc. As well as economic + practical benefits

That preclin data shows the potential of 6103 across a range of indications, really bolstering those tumour agnostic credentials. 3/4

[asininityandbeyond @asininitybeyond]

CUP has massive unmet need + with no specific Tx. A drug with the ability to target a range of indications based on FAP + a broad utility warhead like EXd is perfect for this.

Opens up ODD, accelerated pathways for AVA6103, plus a big Ph2 patient population.2/3 #AVCT

[asininityandbeyond @asininitybeyond]

$LLY acquires CAR-T myeloma focussed Kelonia for up to $7bn. $3.5bn u/f + rest depends on milestones

Lead asset Ph1, <40 pts dosed

Platform tech ➡️ immediate read across to preCISION from Jake “we want the next Enhertu” Van Naarden - simplicity, turn-key, broad potential

#AVCT

[asininityandbeyond @asininitybeyond]

Revolution raises $2bn. Upsized 100% vs initial target of $1bn - placing shares issued at $142. Little to no discount.

Good data opens so many doors.

#AVCT

[asininityandbeyond @asininitybeyond]

“Daraxonrasib achieved OS of 13.2 months compared to 6.7 months for chemotherapy.” - BioSpace

“PFS doesn’t matter”, “Pharma only wants cures” narrative going right out the window.

Giving patients more time really matters. Expect updated AVA6000 data this Q really shines.

#AVCT

[asininityandbeyond @asininitybeyond]

Lilly acquire Crossbridge Bio for $300m.

Lead asset is a dual payload “potential best-in-class TROP2-targeting TOP1i/ATRi ADC”

PRE-IND stage tech.

Very straight forward read across for the value disconnect with #AVCT.

https://t.co/RJMjf7Owni